Loading...
Market
Will GSK's lupus drug enter Phase 3 trials by October 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical trial registries and GSK press releases
Story
GSK Acquires Investigational Lupus Drug from Chimagen Biosciences for $850 Million
Oct 29, 2024, 12:13 PM
GSK has announced the acquisition of an investigational drug from Chinese biotech firm Chimagen Biosciences for up to $850 million. This move aims to enhance GSK's pipeline of potential treatments for lupus, addressing ongoing unmet needs in autoimmune diseases. The acquisition reflects GSK's strategy to expand its portfolio in the competitive biopharmaceutical market, particularly in the area of autoimmune disorders.
View original story
Similar markets
Successful completion of Phase 1 • 25%
Partial success in Phase 1 • 25%
Failure in Phase 1 • 25%
No results announced • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
